License Agreements - Narrative (Details) $ in Thousands							1 Months Ended		3 Months Ended			9 Months Ended	12 Months Ended
		Dec. 02, 2025 USD ($)	Nov. 05, 2025 USD ($)	Sep. 26, 2025 USD ($)	Apr. 28, 2025 USD ($)	Mar. 18, 2025 USD ($)	Dec. 31, 2025 USD ($) shares	Oct. 31, 2025 USD ($)	Mar. 31, 2027 USD ($)	Mar. 31, 2026	Dec. 31, 2024 USD ($)	Dec. 31, 2025 USD ($) employee vote shares	Dec. 31, 2025 USD ($) shares	Mar. 26, 2026 shares
Asset Acquisition [Line Items]
Deferred revenue, current							$ 4,156				$ 0	$ 4,156	$ 4,156
Research and development	[1]										14,034		138,086
Prepaid expenses and other current assets							$ 5,463				38	$ 5,463	$ 5,463
Paragon Option Agreements | Parascent warrant obligation
Asset Acquisition [Line Items]
Warrants, exercisable (in shares) | shares							402,731					402,731	402,731
Paragon Option Agreements | Forecast | Parascent warrant obligation
Asset Acquisition [Line Items]
Warrants, exercisable (in shares) | shares														34,566
License Agreement Terms | Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project | employee												2
Paragon Therapeutics | Paragon Option Agreements
Asset Acquisition [Line Items]
Accounts payable and other current liabilities							$ 100					$ 100	$ 100
Paragon Therapeutics | Paragon Option Agreements | Forecast
Asset Acquisition [Line Items]
Percent of outstanding shares									1.00%	1.00%
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project | employee												2
Number of votes | vote												1
Termination period												30 days
Research and development											$ 13,124		19,356
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments						$ 22,000
Milestone payment					$ 2,500
Restriction period												5 years
Percent reduction to royalty payment due to invalid patent												30.00%
Termination period due to breach of contract												60 days
Sublicense agreement period												30 days
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments				$ 46,000
Milestone payment			$ 5,000					$ 5,000
Percent reduction to royalty payment due to invalid patent												30.00%
Termination period due to breach of contract												60 days
Sublicense agreement period												30 days
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement
Asset Acquisition [Line Items]
Deferred revenue		$ 20,000					20,000					$ 20,000	20,000
Consideration transfer, period		30 days
Development milestone payments		$ 30,000					30,000
Contract with customer, liability							15,000					15,000	15,000
Contract with customer, refund liability							5,000					5,000	5,000
Deferred revenue, current							4,200					4,200	4,200
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement | License
Asset Acquisition [Line Items]
Contract with customer, liability							10,800					10,800	10,800
Kelun-Biotech | License Agreement Terms | CR-001 | Forecast | Collaborative Arrangement
Asset Acquisition [Line Items]
Combination study approval payment									$ 5,000
Kelun-Biotech | License Agreement Terms | SKB105
Asset Acquisition [Line Items]
Consideration transferred		80,000					80,000
Payments to acquire productive assets							72,000
Contingent consideration							8,000
Development milestone payment		345,000
Sale based milestone payment		$ 902,500
Mid-single digits to low-double digits royalty payment, period		18 months
Low-single digits to low-double digits royalty payment, period		24 months
Research and development							78,200
Prepaid expenses and other current assets							$ 1,800					$ 1,800	$ 1,800

[1] Includes related party amount of $23,653 for the twelve months ended months ended December 31, 2025 and $13,185 for the period from September 19, 2024 (inception) through December 31, 2024.